Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The bill directs the Department of Health and Human Services to make public any documents, communications, and other information related to most‑favored‑nation pricing deals and other private drug pricing contracts with manufacturers. It aims to increase transparency for consumers, policymakers, and researchers about how drug prices are set. By shedding light on these confidential agreements, the measure seeks to inform debates on drug costs.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 9699 changes status, plus AI-powered summaries and stage predictions.
Sign up free